Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Treated with DSP-5423P Using PET

Next Previous
X
Search
Trial Profile

Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Treated with DSP-5423P Using PET

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blonanserin (Primary) ; Blonanserin (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Sumitomo Dainippon Pharma

    • Most Recent Events

    • 16 Sep 2020 According to results published in the International Journal of Neuropsychopharmacology, 3 patients in the blonanserin patches 80 mg group were added, and allocation to 10 mg/day was stopped after enrolment of 3 patients, as the observed occupancy at this dose was low.
    • 16 Sep 2020 Results published in the International Journal of Neuropsychopharmacology
    • 09 Sep 2014 Status changed from recruiting to completed, according to the JAPIC Clinical Trials Information record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top